UK kava ban “folly”
This article was originally published in The Tan Sheet
Executive Summary
National Institute of Medical Herbalists condemns UK decision to ban kava as "pure folly," noting Medicines Control Agency ruling "is totally at odds with the evidence available...[and] will harm more patients than it's supposed to protect." In 1Jan. 13 NIMH release, group maintains previous cases of liver toxicity linked to kava "have referred to the use of concentrated extracts rather than the safe traditional use of the herb." Group has started petition and letter-writing campaign to encourage MCA to remove kava ban now in effect (2"The Tan Sheet" Jan. 6, 2003, In Brief)...
You may also be interested in...
Kava banned in UK
Order prohibiting sale, supply, import of kava medicinal products will take effect in UK on January 13, Medicines Control Agency announces. Following examination of 70 reports of adverse liver reactions due to kava consumption - four cases resulting in death, seven in transplants - MCA "concluded that there is clear evidence linking kava...with rare cases of liver disease." However, agency notes it will review the ban in two years to assess whether it remains justified, and can review decision "at any time if new evidence emerges." The UK dietary supplement industry initially agreed to pull kava supplements from store shelves in December 2001 (1"The Tan Sheet" Dec. 24, 2001, p. 14)...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.